Trial of CF101 to Treat Patients With Dry Eye Disease
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24
weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear
production, and patient symptoms.